TM
Our Platform: TriNKET
Dragonfly's proprietary technology: Tri-specific, NK cell Engager Therapies
THE CHALLENGE
Cancer is the leading cause of death worldwide.
Cancer-related deaths are expected to grow to 20 million by 2030, with devastating physical, psychological, and financial effects for families and society broadly.

Immunotherapy has emerged as an effective
alternative to traditional cancer therapies.
In the last decade, immunotherapies have been developed that stimulate the body's immune system to fight cancer, primarily using T-cells. These early immunotherapies have been successful for some patients, but considerable limitations and challenges remain. In particular, T-cell-based treatments have so far been successful only for certain types of cancers, and only for a fraction of patients with those cancers
HOW OUR TECHNOLOGY WORKS
Our proprietary TriNKETs provide an active connection between cancer cells, and cells of the immune system including NK cells themselves, T cells, B cells, and other cells that help attack and kill cancer. Here's how it works:

Start with a cancer cell...
These cancer cells, in both solid tumors and blood, express proteins on their surface.

...and a Natural Killer (NK) Cell
NK cells are part of the natural immune system of every human body. They also express proteins on their surface.

Add Dragonfly’s proprietary TriNKET
Our proprietary TriNKETs (Tri-specific, NK cell Engager Therapies) bind to the proteins expressed on both cancer cells and NK cells.

Activate the body’s NK cells
Through this binding, Dragonfly's TriNKETs stimulate NK cells, making them aware of the cancer and allowing them to both directly kill the cancer cells, and notify other immune cells to attack the cancer.
OUR PIPELINE
Dragonfly's technology for engaging NK cells with tumor targets can be applied to a broad number of cancer types, to both kill cancers directly and help improve the outcomes of other immunotherapy approaches like T-cell therapies.
Our initial pipeline of cancer targets include both key hematological and solid tumor TriNKETs
PRECLINICAL
LEAD SELECTION
FILE IND
Dragonfly Solid Tumor Target DF1001
Dragonfly Heme Tumor Target DF2001
Dragonfly Heme Tumor Target DF2001
Dragonfly Heme Tumor Target DF3001
Dragonfly Solid Tumor Target DFXXX
OUR PIPELINE
Dragonfly's technology for engaging NK cells with tumor targets can be applied to a broad number of cancer types, to both kill cancers directly and help improve the outcomes of other immunotherapy approaches like T-cell therapies.
Our initial pipeline of cancer targets include both key hematological and solid tumor TriNKETs:
DISCOVERY
LEAD SELECTION
FILE IND PHASE I
Dragonfly Solid Tumor Target DF1001
Dragonfly Heme Tumor Target DF2001
Dragonfly Heme Tumor Target DF3001
Dragonfly Heme Tumor Target DF4001
Dragonfly Heme Tumor Target DF5001
Dragonfly TriNKET Enhancer DF6000